-

Allurion Technologies Announces New Hires To Support Rapid Global Expansion and Preparation for US Launch

Whitney Cypes and Chris Aronson join company’s rapidly expanding Commercial team

Benoit Chardon promoted to Executive Vice President of Commercial

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced the addition of Whitney Cypes as Vice President of Global Marketing and Chris Aronson as Vice President of North American Sales and the promotion of Benoit Chardon to Executive Vice President of Commercial.

Whitney Cypes joins the company as Vice President of Global Marketing. Mrs. Cypes is a seasoned marketer with over 15 years of global experience with medical devices. She has launched over a dozen new products across the world and specializes in high growth products marketed to both physicians and consumers, consumer experiences that span medical and digital, and marketing strategies that are designed to scale. Most recently, she was Senior Director of Marketing for Insulet Corporation. Prior to Insulet, Mrs. Cypes held senior marketing roles at Hologic, Boston Scientific, and Covidien.

Chris Aronson joins the company as Vice President of North American Sales. Most recently, Mr. Aronson served as the Vice President of Sales, North America for Restoration Robotics where he built the North American commercial team and helped launch Artas iX, the world’s first robot to fully automate a hair restoration procedure. Prior to Restoration Robotics, Mr. Aronson spent 14 years at Cynosure in a number of senior sales roles prior to Cynosure’s acquisition by Hologic for $1.7B. Over the course of his career, he has developed expertise in highly scalable cash-pay products and experiences and high-performance commercial teams.

Benoit Chardon has been promoted to Executive Vice President of Global Commercial. In his new role, Mr. Chardon will be responsible for driving continued, exponential revenue growth, expanding commercial operations into Latin America, Asia Pacific, and North America, and scaling Allurion Academy, a world class professional education program that debuted in 2019. In his tenure at Allurion, Mr. Chardon and his team have delivered over 100% annual revenue growth, expanded commercial operations to over 30 countries, and deployed best-in-class marketing strategies leading to a radical transformation of both B2B account productivity growth and ROI of demand generation programs. Global Sales, Marketing, Business Excellence, and Professional Education will be reporting to Mr. Chardon in his new role.

“Allurion has developed a best-in-class program to help people lose weight and stay healthy around the world,” says Dr. Shantanu Gaur, Allurion’s co-founder and Chief Executive Officer. “I am looking forward to working with these new additions to our team as we enter our next phase of rapid growth.”

About Allurion Technologies
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company's flagship product, the Elipse Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion or on Twitter @alluriontech.

Contacts

Paul Kidwell
(617) 680-1088

Allurion Technologies


Release Summary
Allurion Technologies US New Hires
Release Versions

Contacts

Paul Kidwell
(617) 680-1088

More News From Allurion Technologies

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and...

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition. Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, results f...

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical’s 30-year experience in the Brazilian market and reflects Allurion’s commitment to establishing a new standard of care in obesity management focused on metabolically h...
Back to Newsroom